A
64.95
0.24 (0.37%)
| Penutupan Terdahulu | 64.71 |
| Buka | 63.74 |
| Jumlah Dagangan | 305,206 |
| Purata Dagangan (3B) | 637,708 |
| Modal Pasaran | 3,576,971,776 |
| Harga / Jualan (P/S) | 30.78 |
| Harga / Buku (P/B) | 7.49 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 May 2025 - 4 Jun 2025 |
| Margin Keuntungan | -99.45% |
| Margin Operasi (TTM) | -348.17% |
| EPS Cair (TTM) | -2.00 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -75.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.89% |
| Nisbah Semasa (MRQ) | 4.78 |
| Aliran Tunai Operasi (OCF TTM) | -83.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 15.04 M |
| Pulangan Atas Aset (ROA TTM) | -11.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -22.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arcellx, Inc. | Bercampur | Menaik |
AISkor Stockmoo
-1.7
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.67 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.32% |
| % Dimiliki oleh Institusi | 109.21% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2024 | 6,720,803 |
| Ra Capital Management, L.P. | 31 Dec 2024 | 2,787,327 |
| Sr One Capital Management, Lp | 31 Dec 2024 | 2,346,630 |
| Cormorant Asset Management, Lp | 31 Dec 2024 | 1,300,000 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2025 | 1,047,557 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Mar 2025 | Pengumuman | Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors |
| 27 Feb 2025 | Pengumuman | Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights |
| 26 Feb 2025 | Pengumuman | Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |